Noubar Afeyan Sells 10,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) Director Noubar Afeyan sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $167.99, for a total transaction of $1,679,900.00. Following the sale, the director now directly owns 2,467,209 shares in the company, valued at $414,466,439.91. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Noubar Afeyan also recently made the following trade(s):

  • On Wednesday, July 27th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $161.00, for a total transaction of $1,610,000.00.
  • On Wednesday, July 20th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $167.00, for a total transaction of $1,670,000.00.
  • On Wednesday, July 13th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $168.88, for a total transaction of $1,688,800.00.
  • On Wednesday, July 6th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $154.85, for a total transaction of $1,548,500.00.
  • On Wednesday, June 29th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $140.47, for a total transaction of $1,404,700.00.
  • On Wednesday, June 22nd, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $127.69, for a total transaction of $1,276,900.00.
  • On Wednesday, June 8th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $147.47, for a total transaction of $1,474,700.00.
  • On Wednesday, June 1st, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $146.31, for a total transaction of $1,463,100.00.
  • On Wednesday, May 25th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $130.80, for a total transaction of $1,308,000.00.
  • On Friday, May 13th, Noubar Afeyan sold 100,000 shares of Moderna stock. The shares were sold at an average price of $134.47, for a total transaction of $13,447,000.00.

Moderna Price Performance

Shares of Moderna stock traded down $7.34 on Friday, reaching $186.84. 5,419,291 shares of the stock were exchanged, compared to its average volume of 6,847,178. The firm’s 50 day moving average is $152.33 and its 200-day moving average is $152.85. Moderna, Inc. has a one year low of $115.61 and a one year high of $497.49. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.56 and a current ratio of 1.99. The firm has a market cap of $74.32 billion, a PE ratio of 5.69, a P/E/G ratio of 1.05 and a beta of 1.61.

Moderna (NASDAQ:MRNAGet Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $5.24 earnings per share for the quarter, topping analysts’ consensus estimates of $4.73 by $0.51. Moderna had a net margin of 61.12% and a return on equity of 94.76%. The company had revenue of $4.73 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the prior year, the firm posted $6.46 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. As a group, analysts anticipate that Moderna, Inc. will post 27.29 EPS for the current fiscal year.

Analyst Ratings Changes

MRNA has been the topic of a number of research reports. SVB Leerink upped their price target on shares of Moderna from $70.00 to $77.00 and gave the company an “underperform” rating in a research note on Monday. Morgan Stanley decreased their price target on shares of Moderna from $199.00 to $197.00 and set an “equal weight” rating on the stock in a research note on Thursday. Finally, Piper Sandler decreased their target price on shares of Moderna from $348.00 to $214.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $226.92.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Confluence Wealth Services Inc. bought a new position in Moderna in the 4th quarter valued at approximately $25,000. Standard Family Office LLC bought a new position in Moderna in the 4th quarter valued at approximately $25,000. Total Clarity Wealth Management Inc. bought a new position in Moderna in the 2nd quarter valued at approximately $25,000. AllSquare Wealth Management LLC bought a new position in Moderna in the 1st quarter valued at approximately $26,000. Finally, IFS Advisors LLC bought a new position in Moderna in the 4th quarter valued at approximately $27,000. Institutional investors own 61.20% of the company’s stock.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

Further Reading

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.